desipramine has been researched along with Obstructive Lung Diseases in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, GH | 1 |
| Michiels, TM | 1 |
| Mahutte, CK | 1 |
| Light, RW | 1 |
1 trial available for desipramine and Obstructive Lung Diseases
| Article | Year |
|---|---|
Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease.
Topics: Aged; Carbon Dioxide; Clinical Trials as Topic; Depressive Disorder; Desipramine; Double-Blind Metho | 1985 |